Postdoctoral Fellow
Pfizer, Inc.
Andover, Massachusetts
Dr. Kari Martyniak, PhD is finishing up a postdoctoral fellowship at Pfizer R&D in the Pharmacokinetics, Dynamics and Metabolism (PDM) group. Her project focused on investigating the species-dependent differences observed in primary hepatocytes after treatment with LNP-mRNA. The overarching goal of this project was to identify key cellular processes underlying the differences to better inform in vitro-to-in vivo extrapolation modeling for improved confidence in therapeutic dose prediction. This was a collaborative effort between the Biomarkers & Biomeasures and Translational Modeling Teams. It involved a variety of techniques including flow cytometry, imaging flow cytometry, digital-PCR, cell-based assays and untargeted proteomics.
Kari completed her PhD in Biomedical Sciences at the University of Central Florida in 2022. In her graduate work Kari designed and characterized complex in vitro model systems for the quantitative analysis of cartilage cell growth, differentiation, and function in correlation with normal tissue physiology. This multidisciplinary project involved both cell and molecular biology and tissue engineering approaches.
Prior to that, Kari completed her Masters in Biomedical Sciences at the University of Central Florida. During that time, she investigated the role of microRNA in obesity and colorectal cancer, contributing to the identification of potential new biomarkers.
Disclosure information not submitted.
Cellular Mechanisms Underlying Species-Related Differences in LNP-mRNA Delivery
Monday, November 10, 2025
3:15 PM - 3:30 PM CT